AccessibilityHelpAbout Us
Johnson & Johnson logo

Johnson & Johnson(NYSE) JNJ

Market Cap$653.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+148,932%
5 Year+90%
1 Year+56%
1 Month+0%
Premium Feature
Moneyball Superscore
79/100
$272.74
+0.56%
+1.52Today
Johnson & Johnson last closing stock price
MetricPriceDate
Last closeUSD 271.222026-09-25
Johnson & Johnson stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.46%USD 269.992026-09-18
1 month+0.45%USD 270.002026-08-26
3 month+7.03%USD 253.412026-06-26
Year to date+33.16%USD 203.672025-12-31
1 year+56.04%USD 173.812025-09-25
3 year+85.74%USD 146.022023-09-26
5 year+89.74%USD 142.942021-09-24
Since inception+148,932.42%USD 0.181968-01-02

Johnson & Johnson Financials at a Glance

Market Cap

$653.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$97.93B

Net Income (TTM)

$21.04B

EPS (TTM)

$8.63

P/E Ratio

31.44

Dividend

$5.28

Beta (Volatility)

0.16 (Low)

Price

$272.74

Volume

2,197,319.627

Open

$270.17

Previous Close

$271.22

Daily Range

$269.27 - $273.49

52-Week Range

$179.80 - $281.07

Estimated Earnings Date

Oct 13, 2026

JNJ News

TMF-Pills-Blue-StockVStock.png

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Brendan CoffeySep 25, 2026
TMF-Pills-Purple-StockVStock.png

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?

Sarah SidlowSep 24, 2026
Investor running away from bear market.

8 Best Bear Market Stocks to Buy in 2026

Rachel WarrenSep 21, 2026
22_04_25 Connected puzzle pieces with the letters M&A on them _GettyImages-1318465425

Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal

Reuben Gregg BrewerSep 21, 2026
Investing

The Investing Playbook for Retirees Who Can't Afford to Lose

Dana GeorgeSep 21, 2026
GettyImages-2209260070-1200x801-d21b45d (1)

Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

Rick OrfordSep 17, 2026
Artificial intelligence robots working in office

10 Companies Using Artificial Intelligence (AI) in Meaningful Ways

Jeremy BowmanSep 16, 2026
GettyImages-woman points at computer with a pen to show something to a colleague.jpg

My Top 5 Favorite Stocks for an Uncertain Market

Adria CiminoSep 16, 2026
Page 1

JNJ: Motley Fool Moneyball Superscore

79

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Johnson & Johnson

Johnson & Johnson makes medicine for sick people. They also create tools for doctors to use in surgery. These products help people stay healthy and recover from illness.

Medicines and Medical Tools

  • Innovative Medicine: Focuses on drugs for cancer, immune disorders, and brain health; sales were $31.8 billion in the fiscal six months of 2026.
  • MedTech: Includes surgical equipment, orthopedic implants, and vision care; sales reached $17.6 billion in the fiscal six months of 2026.
  • Oncology: Medicines for cancer treatment such as Darzalex and Carvykti; generated $14.4 billion in sales during the fiscal six months of 2026.
  • Immunology: Drugs for autoimmune diseases, which are conditions where the body attacks itself; brought in $7.2 billion in the fiscal six months of 2026.
  • Neuroscience: Products for brain health and conditions like major depressive disorder, a form of clinical depression; sales were $4.5 billion in the fiscal six months of 2026.

Moving the Business Forward

  • Acquired Intra-Cellular Therapies on April 2, 2025, to add the neuroscience medicine Caplyta to its product portfolio.
  • Announced a plan in October 2025 to separate the Orthopaedics business into a standalone entity.
  • Introduced new heart procedure technologies including the Varipulse and Trupulse systems in the MedTech segment.
  • Launched a supply chain restructuring program in 2026 to exit certain manufacturing locations and streamline operations.

What Makes Them Different

The company maintains a global operational footprint with $27.9 billion in U.S. sales and $21.5 billion in international sales during the fiscal six months of 2026. It dedicated $7.2 billion to research and development during that same period to fuel its pipeline of new treatments.

The Latest Numbers

  • Worldwide sales reached $49.4 billion in the fiscal six months of 2026, up 8.2% year over year.
  • Operational sales growth, which excludes the impact of changing currency values, was 6.0% for the fiscal six months of 2026.
  • Net earnings for the fiscal six months of 2026 were $10.8 billion.
  • Cash and marketable securities totaled $20.8 billion as of June 28, 2026.
  • Total debt stood at $49.0 billion at the end of the fiscal second quarter of 2026.

Bottom Line

Johnson & Johnson is shifting its focus toward high-margin medicines and medical technology to drive growth. This transformation involves separating its Orthopaedics unit while investing in innovative treatments for cancer and immune diseases.

AI Generated • Jul 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

140,800

CEO

Joaquin Duato, MBA

Website

www.jnj.com

Headquarters

New Brunswick, NJ 08933, US

JNJ Financials

Key Financial Metrics (TTM)

Gross Margin

67.91%

Operating Margin

26.81%

Net Income Margin

21.48%

Return on Equity

25.74%

Return on Capital

19.77%

Return on Assets

10.46%

Earnings Yield

3.18%

Dividend Yield

1.95%

Payout Ratio

59.99%

Stock Overview

Market Cap

$653.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.41B

Volume

2.20M

Avg. Volume

7.19M

Financials (TTM)

Gross Profit

$66.50B

Operating Income

$26.26B

EBITDA

$33.73B

Operating Cash Flow

$23.70B

Capital Expenditure

-$5.00B

Free Cash Flow

$18.71B

Cash & ST Invst.

$20.76B

Total Debt

$49.04B

Johnson & Johnson Performance Analysis

Johnson & Johnson annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 80,062,000,000-14.6%
20232023-12-31USD 85,152,000,0006.4%
20242024-12-31USD 88,819,000,0004.3%
20252025-12-31USD 94,178,000,0006.0%
Johnson & Johnson sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-281.1%
Q42025-12-282.4%
Q12026-03-29-2.0%
Q22026-06-285.2%
Johnson & Johnson annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 6.73-13.7%
20232023-12-31USD 5.53-17.8%
20242024-12-31USD 5.794.6%
20252025-12-31USD 11.0390.6%
Johnson & Johnson sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-28-7.4%
Q42025-12-28-0.9%
Q12026-03-291.9%
Q22026-06-286.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$25.31B

+6.6%

Gross Profit

$17.26B

+7.1%

Gross Margin

68.19%

N/A

Market Cap

$653.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.61M

N/A

Employees

141,700

N/A

Net Income

$5.53B

-0.1%

EBITDA

$8.99B

+2.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$20.76B

+9.9%

Total Debt

$49.04B

-3.4%

Accounts Receivable

$19.05B

+6.7%

Inventory

$15.14B

+12.9%

Long Term Debt

$37.34B

-4.8%

Short Term Debt

$11.69B

+1.4%

Return on Assets

10.46%

N/A

Return on Invested Capital

17.96%

N/A

Free Cash Flow

$3.39B

+36.7%

Operating Cash Flow

$4.71B

+21.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABBVAbbVie Inc.
$267.09+1.04%
MRKMerck & Co., Inc.
$148.49-0.19%
UNHUnitedHealth Group Incorporated
$376.59-0.00%
NVSNovartis AG
$146.56+0.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.42-8.61%
NVDANvidia
$230.43+2.38%
INTCIntel
$115.51-6.09%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.79+7.28%

Questions About JNJ

What is the current price of Johnson & Johnson?

Johnson & Johnson is trading at $273.37 per share.

What is the 52-week range for Johnson & Johnson?

Over the past 52 weeks, Johnson & Johnson has traded between $179.80 and $281.07.

How much debt does Johnson & Johnson have?

As of the most recent reporting period, Johnson & Johnson reported total debt of $49.04B.

How much cash does Johnson & Johnson have on hand?

Johnson & Johnson reported $20.42B in cash and cash equivalents in its most recent financial results.

What is Johnson & Johnson’s dividend yield?

Johnson & Johnson currently has a dividend yield of 1.95%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services